Robot-Guided surgery plus Clot-Busting drug aims to improve brain bleed recovery
NCT ID NCT03957707
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of stereotactic (computer-guided) surgery and a clot-dissolving drug can help people recover from a deep brain hemorrhage. The trial enrolls 380 adults with small-to-moderate bleeds in the basal ganglia who have significant disability. The goal is to see if this precise, personalized approach leads to better functional independence compared to standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- stereotactic surgery plus thrombolytic agent
- What this could lead to
- If successful, this could establish a standard minimally invasive procedure to improve functional independence after a deep brain hemorrhage.
- What could go wrong
- This is a mid-stage trial without a placebo control, and results may not apply to larger bleeds or all patients. Surgery carries risks of infection, rebleeding, or incomplete clot removal.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL GANGLIA HAEMATOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China